"Wilmington Dermatology Center provides Wilmington, NC with cosmetic dermatology, medical dermatology, and aesthetic services. Our exceptionally qualified staff is dedicated to offering the newest products and equipment available, and we're committed to providing you with top-of-the-line treatment and results."

During the past decade, Wilmington Dermatology Center conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 10 clinical trials were completed, i.e. on average, 47.6% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 6 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wilmington Dermatology Center" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Amgen" with 3 trials sponsored, "Ulthera, Inc" with 3 trials sponsored, "AnaptysBio, Inc." with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wilmington Dermatology Center" #1 collaborator was "Dermira, Inc." with 4 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Hexal AG" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Wilmington Dermatology Center" are "Atopic Dermatitis" (5 trials), "Plaque Psoriasis" (5 trials), "Glabellar Lines" (3 trials), "Psoriasis" (3 trials) and "Lateral Canthal Lines" (2 trials). Many other conditions were trialed in "Wilmington Dermatology Center" in a lesser frequency.

Most popular intervention types in "Wilmington Dermatology Center" are "Drug" (17 trials), "Biological" (6 trials), "Device" (5 trials), "Other" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Lebrikizumab" (4 trials), "ABP 654" (2 trials), "BMS-986165" (2 trials) and "MT10109L" (2 trials). Other intervention names were less common.

The vast majority of trials in "Wilmington Dermatology Center" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Wilmington Dermatology Center". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Wilmington Dermatology Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Wilmington Dermatology Center, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".